Technical difficulties · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
It is very uncertain whether telerehabilitation changes technical difficulties with the intervention at 6 months compared with self‐training (very low certainty).
1 finding from 1 review
Device abandonment rate at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of prematurity, retinitis…
It is very uncertain whether telerehabilitation changes device abandonment rate at 6 months compared with self‐training (very low certainty).
1 finding from 1 review
Neuropsychiatric symptoms · dementia or mild neurocognitive disorder
1 finding from 1 review
Leaving the study early · dementia or mild neurocognitive disorder
It is very uncertain whether summary of findings table ‐ DMT changes dropouts compared with exercise (very low certainty).
1 finding from 1 review
Cognitive outcome · dementia or mild neurocognitive disorder
1 finding from 1 review
Depression · dementia or mild neurocognitive disorder
1 finding from 1 review
Social and occupational functioning · dementia or mild neurocognitive disorder
1 finding from 1 review
Dropout · dementia or mild neurocognitive disorder
It is very uncertain whether summary of findings table ‐ DMT changes dropout compared with waiting list (very low certainty).
1 finding from 1 review
Neuropsychiatric symptoms · dementia or mild neurocognitive disorder
1 finding from 1 review
Cognitive function · dementia or mild neurocognitive disorder
1 finding from 1 review
Depression · dementia or mild neurocognitive disorder
1 finding from 1 review
Social and occupational functioning · dementia or mild neurocognitive disorder
1 finding from 1 review
Contraception use · female users or non‐users of contraception
Summary of findings table ‐ Mobile phone‐based interventions probably leads to higher contraception use compared with standard of care (moderate certainty).
1 finding from 1 review
Pregnancy · female users or non‐users of contraception
Summary of findings table ‐ Mobile phone‐based interventions showed no clear difference in pregnancy compared with standard of care (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Change in disability Assessed by: EDSS · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review